Please use this identifier to cite or link to this item: https://www.arca.fiocruz.br/handle/icict/31319

Type
Article
Copyright
Restricted access
Embargo date
2028-01-01
Collections
Share

Statistics
Metadata
Show full item record

RITONAVIR-BOOSTED TIPRANAVIR DEMONSTRATES SUPERIOR EFFICACY TO RITONAVIR-BOOSTED PROTEASE INHIBITORS IN TREATMENT-EXPERIENCED HIV-INFECTED PATIENTS: 24-WEEK RESULTS OF THE RESIST-2 TRIAL
Cahn, Pedro et al. | Date Issued: 2006
Author
Cahn, Pedro
Villacian, Jorge
Lazzarin, Adriano
Katlama, Christine
Grinsztejn, Beatriz
Arasteh, Keikawus
López, Paulo
Clumeck, Nathan
Gerstoft, Jan
Stavrianeas, Nikolas
Moreno, Santiago
Antunes, Francisco
Neubacher, Dietmar
Mayers, Douglas
Affilliation
Fundación Huésped. Buenos Aires, Argentina.
Boehringer Ingelheim GmbH. Ingelheim am Rhein, Germany.
Vila-Salute San Raffaele University. Milan, Italy.
Hôpital de la Pitié-Salpétrière. Paris, France.
Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Rio de Janeiro, RJ, Brasil.
Auguste-Viktoria Klinikum. Berlin, Germany.
Hospital Juan I Menchaca. Instituto Mexicano del Seguro Social. Guadalajara, JAL, Mexico.
Hôpital Universitaire St. Pierre. Bruxelles, Belgium.
Rigshospitalet. Copenhagen, Denmark.
Andreas Syngros Hospital. Athens, Greece.
Hospital Ramón y Cajal. Madrid, Spain.
Hospital de Santa Maria. Lisbon, Portugal.
Boehringer Ingelheim GmbH and Co. KG. Ingelheim am Rhein, Germany.
Boehringer Ingelheim Pharmaceuticals. Ridgefield, CT, USA.
Abstract
Tipranavir, a novel protease inhibitor, has demonstrated antiviral activity against protease inhibitor-resistant human immunodeficiency virus type 1 (HIV-1) isolates. The Randomized Evaluation of Strategic Intervention in multi-drug reSistant patients with Tipranavir (RESIST-2) trial is an ongoing, open-label, phase III trial comparing ritonavir-boosted tipranavir (TPV/r) plus an optimized background regimen with an individually optimized, ritonavir-boosted protease inhibitor in treatment-experienced, HIV-1-infected patients.
Keywords
HIV
HIV-infected patients
Ritonavir-boosted
Tipranavir
 
Publisher
Oxford University Press
Citation
CAHN, Pedro et al. Ritonavir-boosted Tipranavir demonstrates superior efficacy to Ritonavir-boosted protease inhibitors in treatment-experienced HIV-infected patients: 24-week results of the RESIST-2 trial. Clinical Infectious Diseases, v. 43, p. 1347-1356, 2006.
DOI
10.1086/508352
ISSN
1058-4838